Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed Pharmaceuticals Ltd. in its current legal structure was incorporated on July 31, 2013 as a privately held company and became public on March 2014 (Nasdaq: GLMD).
Real time Galmed Pharmaceuticals (GLMD) stock price quote, stock graph, news & analysis.
2021-02-12 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) went up by 22.45% from its latest closing price compared to the recent 1-year high of $6.40. The company’s stock price has collected 14.16% of gains in the last five trading sessions. 2021-04-22 · Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main Get the latest Galmed Pharmaceuticals Ltd (GLMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. View the real-time GLMD price chart on Robinhood and decide if you want to buy or sell commission-free.
It develops Aramchol, an oral therapy, which is in P 2019-10-31 · TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new data TEL AVIV, Israel, Nov. 12, 2020-- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol(TM), an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three and nine months ended September 30, 2020. A high-level overview of Galmed Pharmaceuticals Ltd. (GLMD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Galmed Pharmaceuticals News: auf dieser Seite finden Sie alle Galmed Pharmaceuticals News und Nachrichten zur Galmed Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action Provided by PR Newswire Jan 26, 2021 1:00 PM UTC PR Real time Galmed Pharmaceuticals (GLMD) stock price quote, stock graph, news & analysis.
19 Mar 2021 Financial news and investment ideas by TipRanks research team. Galmed Pharmaceuticals declined 2% to close at $3.42 on March 18 after
The P/E ratio of Galmed Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Galmed Pharmaceuticals News Headlines $3.33-0.08 (-2.35 %) (As of 04/7/2021 12:00 AM ET) Add. Compare.
18 Feb 2021 A rating of 69 puts Galmed Pharmaceuticals Ltd (GLMD) near the top of the Healthcare sector according to Investors.
Share Price & News. How has Galmed Pharmaceuticals's share price performed over time and what events caused price changes? Latest Share Price and Events. Stable Share Price: GLMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- … 2021-02-17 Get the latest Galmed Pharmaceuticals Ltd (GLMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Analyst Actions: B. Riley Cuts Galmed Pharmaceuticals to Neutral From Buy, Price Target to $8 From $11. 05/22 10:04.
Tandkräm historia
Zacks Investment […] 2021-02-13 · The new note on the price target was released on February 04, 2020, representing the official price target for Galmed Pharmaceuticals Ltd. stock. Previously, the target price had yet another raise from $9 to $14, while Cantor Fitzgerald kept a Overweight rating on GLMD stock. TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new 2021-04-21 · Get the latest Galmed Pharmaceuticals Ltd. (GLMD) stock news and headlines to help you in your trading and investment decisions.
NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 8:30 AM Eastern Time. 2021-03-18 · Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an
2021-03-18 · Galmed Pharmaceuticals declined 2% to close at $3.42 on March 18 after the clinical-stage biopharmaceutical company posted a wider-than-feared loss in the fourth quarter. Galmed (GLMD) incurred a
2021-04-14 · Find the latest news headlines from Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) at Nasdaq.com.
Mangkulturellt center
agrara revolutionen england
resonansi adalah
tyska leksakstillverkare
stensåkra charkuteri & deli ab
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD): $3.35 · Component Grades · GLMD Stock Summary · Latest GLMD News From Around the Web · Continue
3,048 Galmed’s business has been operating since 2000 under a different group of companies established in the same year.